Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).

Vincent J. Picozzi; Flavio G. Rocha; Scott Helton; Michael J. Pishvaian; Patrick G Jackson; Kabir Mody; Horacio Asbun; Mairead Carney; Tina Etheridge; Thomas B Neff; Seth Porter; Ming Zhong; Frank Valone; Elias Kouchakji; Joanne C. Imperial; Ewa Carrier

doi:10.1200/jco.2016.34.4_suppl.457

Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).

Vincent J. Picozzi, Flavio G. Rocha, Scott Helton, Michael J. Pishvaian, Patrick G Jackson, Kabir Mody, Horacio Asbun, Mairead Carney, Tina Etheridge, Thomas B Neff, Seth Porter, Ming Zhong, Frank Valone, Elias Kouchakji, Joanne C. Imperial, Ewa Carrier

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	34
DOIs	https://doi.org/10.1200/jco.2016.34.4_suppl.457
State	Published - Feb 1 2016

Disciplines

Medicine and Health Sciences
Pathology
Oncology
Internal Medicine

Access to Document

10.1200/jco.2016.34.4_suppl.457License: Unspecified

Cite this

Picozzi, V. J., Rocha, F. G., Helton, S., Pishvaian, M. J., Jackson, P. G., Mody, K., Asbun, H., Carney, M., Etheridge, T., Neff, T. B., Porter, S., Zhong, M., Valone, F., Kouchakji, E., Imperial, J. C., & Carrier, E. (2016). Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC). Journal of Clinical Oncology, 34. https://doi.org/10.1200/jco.2016.34.4_suppl.457

Picozzi, VJ, Rocha, FG, Helton, S, Pishvaian, MJ, Jackson, PG, Mody, K, Asbun, H, Carney, M, Etheridge, T, Neff, TB, Porter, S, Zhong, M, Valone, F, Kouchakji, E, Imperial, JC & Carrier, E 2016, 'Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).', Journal of Clinical Oncology, vol. 34. https://doi.org/10.1200/jco.2016.34.4_suppl.457

@article{9746bd3cb4404f8db8ca5bf9cf9180c1,

title = "Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).",

author = "Picozzi, \{Vincent J.\} and Rocha, \{Flavio G.\} and Scott Helton and Pishvaian, \{Michael J.\} and Jackson, \{Patrick G\} and Kabir Mody and Horacio Asbun and Mairead Carney and Tina Etheridge and Neff, \{Thomas B\} and Seth Porter and Ming Zhong and Frank Valone and Elias Kouchakji and Imperial, \{Joanne C.\} and Ewa Carrier",

note = "Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by dense stroma and connective tissue growth factor (CTGF) overexpression. Although prolonged overall survival (OS) can be achieved through resection, only approximately 15\% to 20\% of patients are treated with surgery. Previously, pamrevlumab (P), a fully human monoclonal antibody blocking CTGF, was combined with gemcitabine/erlotinib (G/E) in a study of advanced PDAC.",

year = "2016",

month = feb,

day = "1",

doi = "10.1200/jco.2016.34.4\_suppl.457",

language = "American English",

volume = "34",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).

AU - Picozzi, Vincent J.

AU - Rocha, Flavio G.

AU - Helton, Scott

AU - Pishvaian, Michael J.

AU - Jackson, Patrick G

AU - Mody, Kabir

AU - Asbun, Horacio

AU - Carney, Mairead

AU - Etheridge, Tina

AU - Neff, Thomas B

AU - Porter, Seth

AU - Zhong, Ming

AU - Valone, Frank

AU - Kouchakji, Elias

AU - Imperial, Joanne C.

AU - Carrier, Ewa

N1 - Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by dense stroma and connective tissue growth factor (CTGF) overexpression. Although prolonged overall survival (OS) can be achieved through resection, only approximately 15% to 20% of patients are treated with surgery. Previously, pamrevlumab (P), a fully human monoclonal antibody blocking CTGF, was combined with gemcitabine/erlotinib (G/E) in a study of advanced PDAC.

PY - 2016/2/1

Y1 - 2016/2/1

UR - http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.4_suppl.365

U2 - 10.1200/jco.2016.34.4_suppl.457

DO - 10.1200/jco.2016.34.4_suppl.457

M3 - Article

VL - 34

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).

Disciplines

Access to Document

Other files and links

Cite this